Jeff Leiden’s last hurrah
This afternoon, after the market closes, Vertex Pharmaceuticals CEO Jeffrey Leiden will preside over his final quarterly earnings call before ceding the reins in April. And once the analysts have finished their niceties, you can expect a simple question: What are you leaving us to look forward to?
Vertex’s work in cystic fibrosis established a template for any biotech hoping to make a mark on human disease. But with four CF medicines approved and accretive, Wall Street’s focus has turned to Vertex’s pipeline.
The company has a treatment for pain with an unclear path forward and a slew of early-stage rare disease treatments that present some scientific risk. Leiden’s job in his waning tenure will be to convince the world that Vertex, which successfully pivoted away from hepatitis C in the last decade, has a promising third act in its future. And he can start today.
Vertex’s work in cystic fibrosis established a template for any biotech hoping to make a mark on human disease. But with four CF medicines approved and accretive, Wall Street’s focus has turned to Vertex’s pipeline.
The company has a treatment for pain with an unclear path forward and a slew of early-stage rare disease treatments that present some scientific risk. Leiden’s job in his waning tenure will be to convince the world that Vertex, which successfully pivoted away from hepatitis C in the last decade, has a promising third act in its future. And he can start today.
.png)
No hay comentarios:
Publicar un comentario